Skip to main content
Onartuzumab plus erlotinib extended overall survival in MET-positive lung cancer
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Onartuzumab plus erlotinib extended overall survival in MET-positive lung cancer
User login
Username
Password
Reset your password
Type
Lead
score